| Product Unit Size | Cost | Quantity | Stock |
|---|
GSK-1838705A is an inhibitor of anaplastic lymphoma kinase (ALK) and IGF-1R that exhibits anticancer chemotherapeutic activity. This compound inhibits cell and tumor growth in a variety of cancers, including non-small cell lung cancer (NSCLC), neuroblastoma, and large-cell lymphoma.
| Cas No. | 1116235-97-2 |
|---|---|
| Purity | ≥98% |
| Formula | C27H29FN8O3 |
| Formula Wt. | 532.57 |
| Chemical Name | 2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide |
| IUPAC Name | 2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide |
| Synonym | GSK1838705A; GSK 1838705A; GSK1838705 |
| Solubility | DMSO 107 mg/mL (200.91 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Yellow to pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. PMID: 19825801.